BioWorld

July 17, 2009

The 'Rights' Stuff: Offering Gains Pharmacyclics $24M

Rebounding from its 2007 troubles with lung cancer drug Xcytrin, Pharmacyclics Inc. has emerged with a retooled management team, a multiproduct pipeline and a rather unusual - at least for biotech - money-raising strategy. (BioWorld Today) Read More

Amgen to Face Bundling Hits; CMS Rule Tolerable for Others

Tysabri Sales Stay Strong in a Good Biogen Quarter

NewCo News: AngioChem Crossing Barriers in Efforts to Heal the Brain

BDSI's Cancer Pain Film Onsolis Wins FDA OK

Clinic Roundup

Appointments And Advancements

Other News To Note

Today's news in brief

BioWorld

BioWorld briefs for May 12, 2026.

News in brief

BioWorld Asia

BioWorld Asia briefs for May 12, 2026

Alzheimer’s, beyond the brain

BioWorld

Researchers at Daping Hospital in China have reported that liver-targeted delivery of the APOE3-Christchurch (APOE3Ch) variant, a rare protective form of...

Concept art for "unlocking the secrets of the mind"

New assay for drug discovery against chemo-induced peripheral neuropathy

BioWorld Science

A group led by researchers at Boston Children’s Hospital established a scalable and reproducible model of paclitaxel-induced axon degeneration and neurotoxicity...

Hantavirus zoonotic spillover illustration

First cruise ship hantavirus genome points to zoonotic spillover

BioWorld

The initial appraisal of the first complete genome sequence of a hantavirus isolated from a patient in Switzerland who was a passenger on the cruise ship MV...